Breckenridge Pharmaceutical, Inc. recalls
12 recall notices naming Breckenridge Pharmaceutical, Inc. since January 2025, in United States. The most recent was published 17 Jun 2026.
Latest recalls (12)
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules USPFDACGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
- Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release Capsules USPFDACGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
- Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
- Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.